Back to News
Market Impact: 0.3
CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis
Source: reuters.com
Healthcare & BiotechCompany Fundamentals
CSL agreed with Switzerland-based Alentis Therapeutics to co-develop and co-promote a treatment for rare kidney and liver diseases. The deal is worth up to $1.6 billion before development funding; no further financial terms or development milestones were specified.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- ‘Unwelcome and unsafe’: Why Japanese companies are retreating from China at a record pace
- Sen. Mitch McConnell closed a loophole in a hemp law he championed. Now a $28 billion THC industry that gets people high is fighting for survival
- They survived World War II and lost decades, but not 2026. Japan's century-old businesses are disappearing at a record pace
- Can America Break China’s Grip on Rare Earths?
- Tom Cruise suffers one of the worst movie debuts of his career. Reviews were so bad Warner Bros. ran ‘decide for yourself’ ads
- Schneider Electric close to $20 bln deal of U.S. software maker PTC - report